How to Source Non-IMP Supplies for Clinical Trials
Tim Holmes, Manager, Clinical Oversight of Supplies, Biogen, offers considerations on how to obtain non-IMP...
GDPR: The Implications for Clinical Development
Eight months in, Nigel Hughes, Scientific Director JCI-PDR, Janssen, examines the ramifications of GDPR on...
Industry Viewpoints: Patient Recruitment and Expanded Access
In the latest Industry Viewpoint, Howard Fingert speaks to CTA’s Elizabeth Williams about the challenges...
Managing Blinding Requirements in IRT: An Overview
Francesco Spoto, Clinical Project Manager, explores the opportunities of using IRT solutions to manage blinded...
Industry Viewpoints: Clinical Trials in Asia – Key Considerations
Mainfong Ang, Amgen, sits down with CTA’s Jisong Seo about the difficulties of clinical operations...
Observations from GCP Sponsor Inspections
Kevin Anderson, Director, Global Clinical Operations, Alexion Pharmaceuticals, offers a perspective on what he has...
Is the GAIN Act Stimulating Antibiotic R&D?
Christopher J. Pace, PhD, Director of Infectious Diseases, GlobalData, assesses the impact of the GAIN...
Strategic Comparator Sourcing – A Matter of High Priority
Ian Hoban, Pilatus Comparator Solutions, poses some key questions that should be front of mind...
New Data Suggest HCV Remains a Problem in the US
Topias Lemetyinen, Senior Epidemiologist, GlobalData, explains why HCV continues to be an enduring issue in...
How to Enable Greater Budget Forecasting
Ken Olovich, R.Ph., MBA, Sourcing and Financial Director of Chorus, Eli Lilly, explains a model...